

Anti-TNFRSF12A/TWEAKR/CD266 Antibody (Enavatuzumab)

Introduction

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody that targets the TNF-like weak inducer of apoptosis receptor (TWEAK). TWEAK (Fn14; TNFRSF12A) is the natural ligand of the TWEAK receptor (TweakR) and stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody-dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruit and activate myeloid effector cells to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo.

Product parameters

Alternative Names	PDL-192, Enavatuzumab
Target Accession	Q9NP84
Target	TNFRSF12A / TWEAKR / CD266
CAS number	1062149-33-0
Molecular Weight	150 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human TNFRSF12A / TWEAKR / CD266 HEK293 Cell Line were stained with Anti-TNFRSF12A/TWEAKR/CD266 Antibody (Enavatuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.04694 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice

Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.



Note

1. This product is for scientific research use only.



APExBIO Technology
www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

